Argenx
ARGX
#485
Rank
$51.49 B
Marketcap
$824.01
Share price
1.32%
Change (1 day)
46.91%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2026 (TTM): $1.50 Billion USD

According to Argenx 's latest financial reports the company's current earnings are $4.66 Billion USD. In 2025 the company made an earning of $1.27 Billion USD, an increase over its 2024 earnings that were of $85.18 Million USD. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) $1.50 B17.52%
2025 $1.27 B1400.64%
2024 $85.18 M-127.97%
2023 -$0.31 Billion-58.25%
2022 -$0.73 Billion80.17%
2021 -$0.41 Billion
2019 -$0.2 Billion124.86%
2018 -$88.43 Million131.81%
2017 -$38.15 Million
2015 -$18.42 Million
2013 -$11.15 Million